Generation Bio to Present at the 2025 Jefferies Global Healthcare Conference
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced that its President and CEO, Geoff McDonough, M.D., will deliver a presentation at the upcoming Jefferies Global Healthcare Conference. The presentation is scheduled for Wednesday, June 4th, 2025, at 8:10 a.m. ET.
Interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. A replay of the presentation will remain available on the website for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GBIO declined 1.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:10 a.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Generation Bio (GBIO) at the Jefferies Healthcare Conference 2025?
How can I watch Generation Bio's (GBIO) presentation at the Jefferies Conference?
What is Generation Bio's (GBIO) main focus as a company?
